The role of endothelin-1 in the development of pulmonary hypertension and right heart hypertrophy is further substantiated by the fact that several ETA antagonists such as bosentan, macitentan and ambrisentan have been shown to produce beneficial effects in patients with pulmonary hypertension [194,198,217,218]. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.